Home > Back to Publisher > Report Information

Strategic Analysis of the European Markets for Theranostics

Frost & Sullivan
May 26, 2009
53 Pages - SKU: MC2445590

Abstract Table of Contents Related Reports

Countries covered: Europe

This Frost & Sullivan research service titled Strategic Analysis of the European Markets for Theranostics provides a strategic analysis of the theranostics market in Europe. This research service focuses on the current scenario in the market, its dynamics and the regulatory scenario. It also includes competitive analysis and strategic recommendations for current industry challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the key applications of theranostics in the following disease areas: cancer, cardiovascular diseases and neuro disorders.

Market Overview

Theranostics Ushers in Personalised Medicine in Europe - A Milestone in the Drug Therapy Process

Theranostics, an emerging field in clinical diagnostics, focuses on developing specific analysis to predict the most suitable drug for a patient as well as assesses the efficacy of the drug. It uses molecular assays to determine the optimum dose of drugs for a patient, ushering in personalised medicine. Although significant awareness has been created about personalised medicine, its full potential is yet to be tapped. Factors such as cost and regulatory timelines are the key hurdles that need to be addressed at the moment. "The emergence of personalised medicine with the help of theranostics is a milestone in the drug therapy process," says the analyst of this research. "Its targeted approach enables the prescription of only those drugs that are linked to a specific biomarker assay, thereby benefiting the physicians, patients, insurance, and regulatory agencies." The availability of advanced technology to support research projects has resulted in novel therapeutics. As more biomarkers are discovered and their importance known, the need for specific theranostic assays is likely to increase.

However, the high cost associated with genetic testing for the identification of biomarkers poses a challenge to the success of theranostics. The uncertainty associated with the clinical utility of biomarkers discovered will negatively impact the return-on-investment (ROI). "Theranostics is a well understood science, yet pharmaceutical companies have been late adopters," says the analyst. "It is rare to see large pharma and diagnostic companies branding themselves as theranostic companies."

Improved cooperation between drug and diagnostic companies will enhance the success of theranostics. The commercialisation of theranostics will be possible by effective communication with the physicians to understand its penetration in the market. "Companies focusing on theranostics with already licensed drugs can play a key role in reaching out to larger pharmaceutical companies," concludes the analyst. "Pharmaceutical companies should be aware of the importance of linking diagnostics to its drug development process."

Please note that Table of Contents numbering has been standardized and may not match numbering within the publication.
1: Introduction
2: Research Scope and Methodology: 2.1: Scope; 2.2: Methodology
3: Benefits of Theranostics
4: Test Categories of Theranostics
5: Stakeholder Analysis
6: The Pharma-Diagnostics Convergence
7: Unveiling the Opportunities
8: Value Addition to Pharmaceutical Industry: 8.1: The Impact of Convergence
9: Application in Drug Development Process
10: Industry Challenges and Recommendations
11: Key Market Dynamics: Market Drivers
12: Key Market Dynamics: Market Restraints
13: Disease Areas: Overview
14: Case Study - Cambridge Theranostics Ltd: 14.1: Noteworthy Innovation in the Cardio-theranostics Sector
15: Neuro-disorders
16: Special Focus: Oncology
17: Why Cancer is at the Center Stage of Theranostics?
18: Role of Theranostics in Cancer Management
19: Breast Cancer
20: Herceptin: Poster-Child of Theranostics
21: Recent Advances in Cancer Theranostics
22: Competitive Overview
23: Competitive Factor Analysis
24: Key Competitive Areas
25: Drugs with Companion Diagnostic Tests
26: Regulatory Scenario: An Overview
27: Initiatives by FDA and EMEA: 27.1: FDA: Critical Path Initiative; 27.2: EMEA: Innovative Medicines Initiative
28: Pharmacogenomics and EMEA: 28.1: Efforts to Familarise with Pharmacogenomics; 28.2: Activities Associated with Drug Discovery and Development; 28.3: Pharmacogenomics in Clinical Practice; 28.4: Drug-diagnostic Co-development
29: EMEA: Path towards Pharmacogenomics (PGx)
30: Strategic Viewpoint: SWOT Analysis for Theranostics Market
31: Conclusion: Past, Present and the Future
32: The Future of Pharmacogenomics
33: Decision Support Databases
34: Database of Key Industry Participants

More Europe Molecular Assays Reports

Snapshots Denmark Fragrances 2009 by Mintel - Snapshots
Snapdata's Snapshots Denmark Fragrances 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report ...

Europe In Vitro Diagnotics Investment Opportunities, Analysis and Forecasts to 2015 by Global Markets Direct
Europe In Vitro Diagnotics Investment Opportunities, Analysis and Forecasts to 2015 Summary This report is an essential source for in-depth information and data relating to Europe In ...

Assessment of the Molecular Diagnostic Market for RSV NA Tests in UK by Data Information Intelligence GmbH
This is the most comprehensive European market report on the emergent field of molecular diagnostics from the end user perspective. Hospital and private laboratories have ...

Assessment of the Molecular Diagnostic Market for Neisseria Gonorrheae (NG) NA Tests in UK by Data Information Intelligence GmbH
This is the most comprehensive European market report on the emergent field of molecular diagnostics from the end user perspective. Hospital and private laboratories have ...

Assessment of the Molecular Diagnostic Market for Human Metapneumovirus (hMPV) NA Tests in UK by Data Information Intelligence GmbH
This is the most comprehensive European market report on the emergent field of molecular diagnostics from the end user perspective. Hospital and private laboratories have ...

See all reports like this >>

More Europe Reports

A Comprehensive Study Of The UK Video Conferencing Equipment Market In 2010, Rating & Valuing Each Of The 30 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Tableware Market In 2010, Rating & Valuing Each Of The 166 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Surveyors & Valuers Market In 2010, Rating & Valuing Each Of The 943 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Subsea Engineering Market In 2010, Rating & Valuing Each Of The 142 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Structural Engineering Consultancy Market In 2010, Rating & Valuing Each Of The 300 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

See all reports like this >>

Strategic Analysis of the European Markets for Theranostics

Share this report

Other tasks

Research Assistance

Related Markets

Molecular Assays Reports

Free Alert Me service